WHO ICTRP trial
A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy…
JPRN-UMIN000026525 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000026525 |
|---|---|
| Public title | A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer |
| Scientific title | A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer - A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer |
| Primary sponsor | Chiba Cancer Center |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Locally advanced pancreatic cancer |
| Interventions | GEM+nab-PTX for 12 weeks or 3cycles: nab-PTX 125mg/m2 day1, 8, 15 every 4 weeks GEM 1000 mg/m2 day1, 8, 15 every 4 weeks S-1+RT: S-1 80/100/120 mg/day based on BSA, day1-14 and 22-35 RT 1.8Gy/day, 28fractions, total 50.4Gy |
| Registration date | Mar 13, 2017 |
| Target size | 30 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: